Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CASI's In-licensed CAR-T Candidate to Start China Trials for Leukemia/Lymphoma

publication date: Dec 4, 2019

CASI Pharma announced China approval to start clinical trials of CNCT19, a CD19 CAR-T treatment, in leukemia and lymphoma patients. Earlier this year, CASI acquired global rights to the candidate from Juventas Cell Therapy of Beijing in exchange for an $11.6 million investment in Juventas rather than an upfront payment. Juventas retains responsibility for trials of CNCT19. CASI, a Maryland-China biopharma, said the CD19 CAR-T therapy will be tested in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and relapsed/refractory B-cell non-Hodgkin lymphoma. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.